Log In
BCIQ
Print this Print this
 

SM301

  Manage Alerts
Collapse Summary General Information
Company Shire plc
DescriptionIgE mAb targeting Fc gamma receptor IIb (CD32B; FCGR2B)
Molecular Target Fc gamma receptor IIb (FCGR2B) (CD32B)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationAllergy
Indication DetailsTreat allergies
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$223.9M

$223.9M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/04/2015

$223.9M

$223.9M

0

Get a free BioCentury trial today